Clinical Trial Update: A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHD [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating flexible-dose titration of Aptensio XR in young children (ages 4 to under 6) with ADHD has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• APTENSIO XR (METHYLPHENIDATE HYDROCHLORIDE)

Snippet

Sponsor: Rhodes Pharmaceuticals, L.P. | Conditions: Attention Deficit Disorder With Hyperactivity | Phase 4 | Status: COMPLETED | Results posted: 2023-02-21